Regarding hospitalizations among immunocompetent older adults, vaccine effectiveness was 83% for the GSK vaccine and 73% for ...

Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...

GlaxoSmithKline (GSK) has received approval for its vaccine, AREXVY, in Canada to prevent lower respiratory tract disease ...

Getting the annual RSV shot and other important vaccines is a fantastic way to safeguard yourself and your family as winter ...

The CDC recommends a single dose of any FDA-approved respiratory syncytial virus (RSV) vaccine for all adults ages 75 years ...

British drugmaker GlaxoSmithKline sued Moderna in U.S. federal court in Delaware on Tuesday, accusing it of violating GSK patent rights in messenger RNA technology with its blockbuster COVID-19 ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

HONG KONG SAR - Newswire - 30 October 2024 - AIM Vaccine (06660.HK), the leader in Chinese mRNA vaccines, announced on 30 th October that mRNA respiratory syncytial virus (RSV) vaccine developed by a ...

Health Canada has approved Moderna’s mRNA vaccine to protect against respiratory syncytial virus in adults age 60 and older – ...

Mississauga: GSK's AREXVY (respiratory syncytial virus vaccine - recombinant, AS01E adjuvanted) has been approved in Canada ...

(Reuters) -British drugmaker GlaxoSmithKline sued Moderna in ... RNA technology with its blockbuster COVID-19 vaccine Spikevax and RSV shot mResvia. According to the two lawsuits, Moderna's ...